Jonathan Rowland increased his stake in fire suppression technology company Zenova Group (LON: ZED) to 7.8%. The share price rebounded 45.5% to 0.8p.
Clinical antibodies supplier Fusion Antibodies (LON: FAB) was highlighted by Zak Myr on his Bulletin Board Heroes broadcast on Thursday. According to his assessment of the chart he was targeting 9.25p by the end of January. He said that the next major resistance point is 10p. There were 3.1 million shares traded on Thursday and on Friday. The share price was 45% higher at 10.15p, which suggests that there could be further improvement.
Trading in Gfinity (LON: GFIN) shares was suspended on 2 January because accounts for the year to June 2024 have been delayed and were not be published by the end of 2024. Gfinity achieved monthly profitability in November. The share price increased 36.4% to 0.075p.
Revolution Beauty (LON: REVB) has come to a confidential agreement with Chrysalis Investments (LON: CHRY) over the claims related to its investment in the company when it joined AIM in July 2021. Last year, Chrysalis Investments issued draft particulars of a claim £39m plus additional consequential loss of £6.2m. Chrysalis Investments will be paid a non-material amount of cash with out admission of liability. This removes a hangover on the Revolution Beauty share price, which recovered 36.3% to 19.76p.
Tungsten West (LON: TUN) had £40,000 in cash at the end of September 2024. There is a provisional agreement to place a further £2.8m of loan notes. Progress is being made towards the reopening of the Hemerdon tungsten and tin mine in Devon. The share price rose 24.2% to 4.1p.
FALLERS
Poolbeg Pharma (LON: POLB) is in talks with potential bidder HOOKIPA Pharma (NASDAQ: HOOK) about an all-share offer from the Nasdaq-listed company. The indicated proposal is 0.03 of a HOOKIPA share for each Poolbeg share. Cancer and infectious disease treatments developer HOOKIPA intends to raise up to $30m. That will fund phase 2a trails for POLB 001 and trials of two other treatments. HOOKIPA shareholders would receive a contingent value right instrument entitling them to 55% of milestone payments made by Gilead for HB-400 and HB-500 programmes. This could be worth up to $407.5m. They are also entitled to 80% of the proceeds generated by the HB-200 programme. The Poolbeg Pharma share price dived 41.7% to 4.2p.
Trading in ADM Energy (LON: ADME) shares was restored following the publication of 2023 accounts and interims for 2024. In 2023, there was a £16.8m impairment charge. There was £66,000 in cash at the end of June 2024 and two investments have generated cash, but ADM Energy is still constrained by a lack of cash. The share price slumped 41.2% to 0.25p.
Pri0r1ty Intelligence Group (LON: PR1) joined AIM on 30 December following the reversal of the AI customer relationship technology company into Alteration Earth. The business provides AI tools to automate areas such as social media and governance for smaller companies. Spreadex has sold a 3.99% stake and retains voting rights through financial instruments of 0.75%. The share price declined by 24.1% from the placing price to 10.25p, although it is 18% down on the Alteration Earth suspension price of 12.5p.
Spreadex Ltd has cut its shareholding, via voting rights through financial instruments, in Tiger Royalties and Investments (LON: TIR) from 4.94% to 3.53%. The company is in the process of acquiring a technology incubator business. The share price slipped 22.2% to 0.175p.
Security technology developer Thruvision (LON: THRU) has appointed Victoria Balchin as chief executive. She was appointed finance director in October 2022 and she is retaining the role. Tom Black will continue as executive chairman and focus on sales. The share price declined 18.7% to 6.5p.